RETRACTED ARTICLE: Thiophen urea derivatives as a new class of hepatitis C virus entry inhibitors

Abstract

To develop unique small-molecule inhibitors of hepatitis C virus (HCV), thiophen urea (TU) derivatives were synthesised and screened for HCV entry inhibitory activities. Among them, seven TU compounds exhibited portent anti-viral activities against genotypes 1/2 (EC 50 < 30 nM) and subsequently, they were further investigated; based on the pharmacological, metabolic, pharmacokinetic, and safety profiles, J2H-1701 was selected as the optimised lead compound as an HCV entry inhibitor. J2H-1701 possesses effective multi-genotypic antiviral activity. The docking results suggested the potential interaction of J2H-1701 with the HCV E2 glycoprotein. These results suggest that J2H-1701 can be a potential candidate drug for the development of HCV entry inhibitors.

Role of Ras-related Nuclear Protein/Polypyrimidine Tract Binding Protein in Facilitating the Replication of Hepatitis C Virus

“… 2 However, the implementation of these approaches is complicated by the cost, potential for reinfection, generation of drug-resistant viruses, reactivation of other viruses, and end-stage liver disease progression that occurs even after virus clearance. 3 , 4 HCV also remains the sole hepatitis virus for which a vaccine is not yet available. Thus, novel prophylactic and therapeutic approaches for HCV are still necessary.…”